Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Business Wire
– On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024 –– Advanced Phase 2 LYNX and FOX trials of sevasemten in children and adolescents with Duchenne –– Advanced Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM) –– Announced positive top-line data from Phase 1 trial in healthy subjects and Phase 2 CIRRUS-HCM trial in patients with obstructive HCM – BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.“We continue to make strong progress on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Based on the strength of clinical and preclinical data to-date, we are treating patients with obstructive and non-obstructive H
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $45.00 price target on the stock.MarketBeat
- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Wedbush from $44.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Piper Sandler from $48.00 to $51.00. They now have an "overweight" rating on the stock.MarketBeat
- Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle SocietyBusiness Wire
- Edgewise's EDG-7500 shows benefit in two obstructive HCM trials [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 8/8/24 - Beat
EWTX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- EWTX's page on the SEC website